Abstract
In most mammals purine degradation ultimately leads to the formation of allantoin. Humans lack the enzyme uricase, which catalyzes the conversion of uric acid to allantoin. The resulting higher level of uric acid has been hypothesized to play a role as an antioxidant. Hyperuricaemia is usually an asymptomatic condition which is hypothesized to play a role in cardiovascular disease and hypertension. Some hyperuricaemic individuals develop gout, an inflammatory arthritis caused by the deposition of monosodium urate crystals in joints. Over time, acute intermittent gouty arthritis can develop into a chronic condition with deposits of monosodium urate (MSU) crystals in joints and as tophi. The mechanisms by which MSU crystals lead to an acute inflammatory arthritis are under investigation and current knowledge is reviewed here. Treatment of gout includes management of acute flares with anti-inflammatory medications such as non-steroidal anti-inflammatory drugs or corticosteroids and long term management with urate-lowering therapy when indicated. Future directions in the treatment of gout, in part guided by a better understanding of pathophysiology, are discussed.
Keywords: Hyperuricaemia, gout, xanthine oxidase inhibitors, uricase
Current Pharmaceutical Design
Title: Overview of Hyperuricaemia and Gout
Volume: 11 Issue: 32
Author(s): D. Masseoud, K. Rott, R. Liu-Bryan and C. Agudelo
Affiliation:
Keywords: Hyperuricaemia, gout, xanthine oxidase inhibitors, uricase
Abstract: In most mammals purine degradation ultimately leads to the formation of allantoin. Humans lack the enzyme uricase, which catalyzes the conversion of uric acid to allantoin. The resulting higher level of uric acid has been hypothesized to play a role as an antioxidant. Hyperuricaemia is usually an asymptomatic condition which is hypothesized to play a role in cardiovascular disease and hypertension. Some hyperuricaemic individuals develop gout, an inflammatory arthritis caused by the deposition of monosodium urate crystals in joints. Over time, acute intermittent gouty arthritis can develop into a chronic condition with deposits of monosodium urate (MSU) crystals in joints and as tophi. The mechanisms by which MSU crystals lead to an acute inflammatory arthritis are under investigation and current knowledge is reviewed here. Treatment of gout includes management of acute flares with anti-inflammatory medications such as non-steroidal anti-inflammatory drugs or corticosteroids and long term management with urate-lowering therapy when indicated. Future directions in the treatment of gout, in part guided by a better understanding of pathophysiology, are discussed.
Export Options
About this article
Cite this article as:
Masseoud D., Rott K., Liu-Bryan R. and Agudelo C., Overview of Hyperuricaemia and Gout, Current Pharmaceutical Design 2005; 11 (32) . https://dx.doi.org/10.2174/138161205774913318
DOI https://dx.doi.org/10.2174/138161205774913318 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide Synthase Function in Exercise
Current Enzyme Inhibition Relations of Magnesium Intake with Metabolic Risk Factors and Risks of Type 2 Diabetes, Hypertension, and Cardiovascular Disease: A Critical Appraisal
Current Nutrition & Food Science The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews Metabolic Syndrome and Aging: Calcium Signaling as Common Regulator
Current Diabetes Reviews Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals Melanogenesis and Melanosome Transportation Modulators from Medicinal Plants
Letters in Drug Design & Discovery Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Cardiovascular & Hematological Disorders-Drug Targets Optimization of Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets Effects of Senna didymobotrya Root Extract and Compounds on Tritoninduced Hyperlipidaemic Rats and Differentiation of 3T3-Li Preadipocytes
The Natural Products Journal Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Use and Results of Antidepressant Treatment: Patients' Perception
Current Drug Therapy Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Medical Therapy for Long QT Syndrome
Mini-Reviews in Medicinal Chemistry